Home
About
Overview
Sharing Data
ORCID
Help
History (3)
A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC).
Newly synthesized glycoprotein profiling to identify molecular signatures of warm ischemic injury in donor lungs.
Tumour lysis syndrome: new therapeutic strategies and classification.
See All 3 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Tumour lysis syndrome: new therapeutic strategies and classification.
Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004 Oct; 127(1):3-11.
View in:
PubMed
subject areas
Allopurinol
Humans
Tumor Lysis Syndrome
Water-Electrolyte Imbalance
authors with profiles
Michael Bishop